Depression and Anxiety Trial, Recruiting NCT04788524 Sponsor: Mclean Hospital Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT04788524
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Female participants of any ethnic background.
  • Adolescents aged 14 to 18 years old.
  • Those who can provide written agreement to participate, along with agreement from a parent or guardian for participants under 18.
  • People whose first language is English, or who are fluent in English.
  • People who are right-handed.
  • People who own a personal mobile phone (used for a type of regular survey during the study).
  • People who are in a specific part of their menstrual cycle (the follicular phase) at the time of the brain scan session.

For the depression group specifically, people who:

  • Have been diagnosed with Major Depressive Disorder (MDD) according to a standard medical assessment.
  • Have not taken any psychiatric medications for a set period of time before joining — the length of time varies depending on the medication (confirm with trial site for details on specific medications).

For the healthy comparison group specifically, people who:

  • Have no current or past diagnosis of any psychiatric condition or substance use disorder.
  • Have no close family members (parents, siblings, or children) with a history of depression, bipolar disorder, or psychosis.

Who may not be able to join:

  • People with a history of a head injury that caused loss of consciousness.
  • People with a history of seizures or a seizure disorder.
  • People with a serious or unstable physical health condition affecting the heart, liver, kidneys, lungs, hormonal system, nervous system, or blood.
  • People with a history of using cocaine, amphetamines, methamphetamine, or similar stimulant drugs.
  • People with a history of using dopamine-affecting drugs, including methylphenidate (a medication used for ADHD).
  • People currently using hormone replacement therapy, anabolic steroids, or hormonal contraception (such as the pill).
  • People with clinical or test-confirmed signs of an underactive thyroid.
  • People with a physical or neurological condition that could affect the results of a brain scan measuring blood flow.
  • People who cannot safely undergo an MRI scan — for example, due to claustrophobia, a pacemaker, surgically implanted metal devices, cochlear implants, metal braces, or other metal in the body.
  • People who are currently pregnant.
  • People who test positive for certain substances on a drug test taken on the day of the scan (including stimulants, marijuana, benzodiazepines, opiates, and several others).
  • People who have previously had electroconvulsive therapy (ECT).
  • People for whom the study clinician considers participation to be unsafe due to thoughts of suicide.

For the depression group specifically:

  • People whose depression diagnosis is considered to be caused by another condition, rather than being the primary diagnosis (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Emily L Belleau, PhD, Mclean Hospital

Phone: 6178554245

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Mclean Hospital
Registry
ClinicalTrials.gov
Start date
23 April 2021
Est. completion
31 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Blood-Oxygen-Level-Dependent Imaging (BOLD) activation of the ventral striatum and ventral medial prefrontal cortex

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov